We are analyzing https://link.springer.com/article/10.1007/s00280-018-3642-4.

Title:
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation | Cancer Chemotherapy and Pharmacology
Description:
Purpose Erlotinib is an essential drug for non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations. The relationship between the pharmacokinetics and skin rash and diarrhea of erlotinib in Chinese patients with EGFR mutated NSCLC is unknown. In this study, we evaluated the variability in erlotinib trough concentration and its relationship with the severity of skin rash and diarrhea in patients with two common types of EGFR mutations: a deletion in exon 19 and point mutations in exon 21 L858R. Patients and methods EGFR mutation-positive Chinese patients (n = 52) treated with erlotinib were included in our study; the steady-state trough concentrations were assessed; and the occurrence and severity of skin rash and diarrhea after the onset of treatment with erlotinib were recorded. The patients were divided into two groups by mutation type (exon 19 deletions or exon 21 L858R point mutations). Occurrence and severity of skin rash and diarrhea was analyzed in both groups. Results The overall mean (± SD) steady-state trough concentration for erlotinib was 1380 ± 663 ng/mL, and there was no significant difference of erlotinib concentrations between the two mutation groups. Occurrence and severity of skin rash was significantly associated with trough concentration in patients with exon 19 deletions but not exon 21 L858R point mutations. Significant association of erlotinib concentrations with diarrhea was found neither in the exon 19 deletions group nor in the exon 21 L858R point mutation group. Conclusions The occurrence and severity of skin rash correlated with increase in erlotinib trough concentrations only in Chinese patients with exon 19 deletion; the erlotinib trough concentrations were not associated with diarrhea.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, cancer, scholar, google, erlotinib, pubmed, patients, cas, lung, skin, rash, exon, egfr, factor, cell, growth, zhang, nonsmall, epidermal, mutations, trough, receptor, concentration, res, mutation, drug, study, tyrosine, kinase, clin, content, diarrhea, oncol, privacy, cookies, search, chinese, nsclc, manuscript, severity, point, concentrations, nonsmallcell, med, inhibitors, httpsdoiorgsx, data, publish, chemotherapy, plasma,

Topics {✒️}

small-cell lung cancer month download article/chapter advanced egfr mutation-positive atp-binding cassette subfamily bcr-abl tyrosine kinase related subjects steady-state trough concentration abcg2-mediated efflux transport steady-state trough concentrations egfr gene polymorphisms tyrosine kinase inhibitors article cancer chemotherapy small molecule inhibitor anti-egfr therapy full article pdf central south university egfr mutated nsclc privacy choices/manage cookies skin rash correlated low plasma concentration erlotinib trough concentration advanced-stage nsclc individualized cancer pharmacotherapy point mutations hunan cancer hospital article liao egfr mutations erlotinib versus chemotherapy erlotinib trough concentrations lung cancer therapeutic drug monitoring gairard-dory a exon 21 mutations elderly patients ≥75 years european economic area evolving genomic classification healthy male volunteers ashby cr jr le deley mc chronic myeloid leukemia exon 19 deletion advanced solid malignancies exon 21 l858r conditions privacy policy egfr exon 19 erlotinib metabolic ratio blood-brain barrier anticancer drugs part von hoff dd pinter-brown lc

Questions {❓}

Dempke WC, Edvardsen M, Lu K, Reinmuth S, Reck N, Inoue M A (2015) Brain metastases in NSCLC—are TKIs changing the treatment strategy?
Petit-Jean EBT, Guidi M, Quoix E, Gourieux B, Decosterd LA, Gairard-Dory A-C, Ubeaud-Séquier G, Widmer N (2015) Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer?
Petrelli F, Borgonovo K, Barni S (2016) Preventing or treating anti-EGFR related skin rash with antibiotics?
Steffens M, Paul T, Hichert V, Scholl C, von Mallek D, Stelzer C, Sorgel F, Reiser B, Schumann C, Rudiger S, Boeck S, Heinemann V, Kachele V, Seufferlein T, Stingl J (2016) Dosing to rash?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation
         description:Erlotinib is an essential drug for non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations. The relationship between the pharmacokinetics and skin rash and diarrhea of erlotinib in Chinese patients with EGFR mutated NSCLC is unknown. In this study, we evaluated the variability in erlotinib trough concentration and its relationship with the severity of skin rash and diarrhea in patients with two common types of EGFR mutations: a deletion in exon 19 and point mutations in exon 21 L858R. EGFR mutation-positive Chinese patients (n = 52) treated with erlotinib were included in our study; the steady-state trough concentrations were assessed; and the occurrence and severity of skin rash and diarrhea after the onset of treatment with erlotinib were recorded. The patients were divided into two groups by mutation type (exon 19 deletions or exon 21 L858R point mutations). Occurrence and severity of skin rash and diarrhea was analyzed in both groups. The overall mean (± SD) steady-state trough concentration for erlotinib was 1380 ± 663 ng/mL, and there was no significant difference of erlotinib concentrations between the two mutation groups. Occurrence and severity of skin rash was significantly associated with trough concentration in patients with exon 19 deletions but not exon 21 L858R point mutations. Significant association of erlotinib concentrations with diarrhea was found neither in the exon 19 deletions group nor in the exon 21 L858R point mutation group. The occurrence and severity of skin rash correlated with increase in erlotinib trough concentrations only in Chinese patients with exon 19 deletion; the erlotinib trough concentrations were not associated with diarrhea.
         datePublished:2018-07-23T00:00:00Z
         dateModified:2018-07-23T00:00:00Z
         pageStart:551
         pageEnd:559
         sameAs:https://doi.org/10.1007/s00280-018-3642-4
         keywords:
            Erlotinib
            EGFR
            Skin rash
            Diarrhoea
            Trough concentration
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-018-3642-4/MediaObjects/280_2018_3642_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-018-3642-4/MediaObjects/280_2018_3642_Fig2_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:82
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Dehua Liao
               affiliation:
                     name:Central South University
                     address:
                        name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
                        type:PostalAddress
                     type:Organization
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dunwu Yao
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ni Liu
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lizhi Cao
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daxiong Xiang
               affiliation:
                     name:Central South University
                     address:
                        name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Nong Yang
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Yongchang Zhang
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wenjuan Jiang
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chunhua Zhou
               affiliation:
                     name:Hunan Cancer Hospital
                     address:
                        name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation
      description:Erlotinib is an essential drug for non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations. The relationship between the pharmacokinetics and skin rash and diarrhea of erlotinib in Chinese patients with EGFR mutated NSCLC is unknown. In this study, we evaluated the variability in erlotinib trough concentration and its relationship with the severity of skin rash and diarrhea in patients with two common types of EGFR mutations: a deletion in exon 19 and point mutations in exon 21 L858R. EGFR mutation-positive Chinese patients (n = 52) treated with erlotinib were included in our study; the steady-state trough concentrations were assessed; and the occurrence and severity of skin rash and diarrhea after the onset of treatment with erlotinib were recorded. The patients were divided into two groups by mutation type (exon 19 deletions or exon 21 L858R point mutations). Occurrence and severity of skin rash and diarrhea was analyzed in both groups. The overall mean (± SD) steady-state trough concentration for erlotinib was 1380 ± 663 ng/mL, and there was no significant difference of erlotinib concentrations between the two mutation groups. Occurrence and severity of skin rash was significantly associated with trough concentration in patients with exon 19 deletions but not exon 21 L858R point mutations. Significant association of erlotinib concentrations with diarrhea was found neither in the exon 19 deletions group nor in the exon 21 L858R point mutation group. The occurrence and severity of skin rash correlated with increase in erlotinib trough concentrations only in Chinese patients with exon 19 deletion; the erlotinib trough concentrations were not associated with diarrhea.
      datePublished:2018-07-23T00:00:00Z
      dateModified:2018-07-23T00:00:00Z
      pageStart:551
      pageEnd:559
      sameAs:https://doi.org/10.1007/s00280-018-3642-4
      keywords:
         Erlotinib
         EGFR
         Skin rash
         Diarrhoea
         Trough concentration
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-018-3642-4/MediaObjects/280_2018_3642_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-018-3642-4/MediaObjects/280_2018_3642_Fig2_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:82
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Dehua Liao
            affiliation:
                  name:Central South University
                  address:
                     name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
                     type:PostalAddress
                  type:Organization
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dunwu Yao
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ni Liu
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lizhi Cao
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daxiong Xiang
            affiliation:
                  name:Central South University
                  address:
                     name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Nong Yang
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Yongchang Zhang
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wenjuan Jiang
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chunhua Zhou
            affiliation:
                  name:Hunan Cancer Hospital
                  address:
                     name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:82
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Central South University
      address:
         name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Central South University
      address:
         name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
      name:Hunan Cancer Hospital
      address:
         name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Dehua Liao
      affiliation:
            name:Central South University
            address:
               name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
               type:PostalAddress
            type:Organization
            name:Hunan Cancer Hospital
            address:
               name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      name:Dunwu Yao
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      name:Ni Liu
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      name:Lizhi Cao
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      name:Daxiong Xiang
      affiliation:
            name:Central South University
            address:
               name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Nong Yang
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Yongchang Zhang
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      name:Wenjuan Jiang
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
      name:Chunhua Zhou
      affiliation:
            name:Hunan Cancer Hospital
            address:
               name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
      name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
      name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
      name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
      name:Department of Pharmacy, Hunan Cancer Hospital, Changsha, China
      name:Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China
      name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
      name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
      name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
      name:Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(1)

https://link.springer.com/article/10.1007/s00280-018-3642-4/mailto:[email protected]

External Links {🔗}(162)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.72s.

LINK . SPRINGER . COM {}